Updated: Apr 2025
91%
Employees say this is a great place to work
Our core business is the development and marketing of medicines. Over 230,000 people in Switzerland are currently being treated with an AstraZeneca medicine. We expect over 35 new therapies to be approved by 2026. We are constantly striving to do our part to make the Swiss healthcare system more sustainable, robust and fit for the future. With this goal in mind, we work together with various stakeholders - far beyond our core business.
Zug
Certification May 2024
Certification February 2023
Certification April 2021
Certification March 2020
Certification March 2019
No Data Found
English 
Deutsch 
Français 
